B Acute Lymphoblastic Leukemia, BCR-ABL1-Like

Oncology·MeSH: Leukemia, Biphenotypic, Acute

Prevalence

30.0 / 100K

0 drugs in development·0 companies·1 clinical trial

Frequently asked questions

How many clinical trials target B Acute Lymphoblastic Leukemia, BCR-ABL1-Like?

There are 1 clinical trial targeting B Acute Lymphoblastic Leukemia, BCR-ABL1-Like tracked by BioSniper.

What is the prevalence of B Acute Lymphoblastic Leukemia, BCR-ABL1-Like?

The estimated prevalence of B Acute Lymphoblastic Leukemia, BCR-ABL1-Like is approximately 30.0 per 100,000 population.

Deep-dive into B Acute Lymphoblastic Leukemia, BCR-ABL1-Like

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    B Acute Lymphoblastic Leukemia, BCR-ABL1-Like — Drugs in Development & Clinical Trials | BioSniper